Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
98 EUR | -1.01% | -.--% | +2.08% |
22/05 | Swiss Equities Tumble as UK Inflation Data Dampens June Rate Cut Hopes | MT |
22/05 | Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 60.05 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.08% | 723B | - | ||
+32.22% | 598B | B | ||
-2.07% | 364B | C+ | ||
+20.25% | 331B | B- | ||
+2.99% | 288B | C+ | ||
+16.60% | 244B | B+ | ||
+9.77% | 210B | B- | ||
-5.15% | 208B | A+ | ||
+7.43% | 169B | C+ | ||
+2.81% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LLY Stock
- LLY Stock
- Ratings Eli Lilly and Company